Skip to content
PaperFren

Addiction

Do GLP-1 drugs lower AUD hospitalizations?

Lähteenvuo M, Tiihonen J, Solismaa A, et al. · JAMA psychiatry · 2025

Open access · cc by · source: Europe PMC

In 227,866 Swedes with AUD, semaglutide (aHR 0.64) and liraglutide (aHR 0.72) use periods had lower AUD hospitalization risk than nonuse—stronger than approved AUD meds overall.

Save to libraryView originalAsk PaperFrenStudy this in NoteFren

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

  • SupportsGLP-1 receptor agonistsconcept

    Semaglutide/liraglutide are being explored beyond glycemic control (e.g., alcohol use disorder).

    Repurposing work examines semaglutide and liraglutide for alcohol use disorder—illustrating that receptor class claims travel across indications carefully.

    Evidence for the claim as stated.

Study at a glance

Design
Cohort — Swedish register cohort with within-individual Cox models of GLP-1 agonist exposure
N
N=227866 · Residents aged 16–64 with AUD diagnosis; GLP-1 users are a subset
Population
Nationwide Swedish individuals with alcohol use disorder (2006–2023 follow-up)
Outcome
Hospitalization for AUD (primary); SUD, somatic hospitalization, suicide attempt (secondary)

Structured fields used in claim comparison tables when every cited study has a complete layer.

Inspect source passages

Do GLP-1 drugs lower AUD hospitalizations?

These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.

Cohort included 227,866 individuals with AUD; 58.5% had AUD hospitalization.

The cohort included 227 866 individuals with AUD; 144 714 (63.5%) were male and 83 154 (36.5%) were female, with a mean (SD) age of 40.0 (15.7) years. Median (IQR) follow-up time was 8.8 (4.0-13.3) years. A total of 133 210 individuals (58.5%) experienced AUD hospitalization.

Semaglutide associated with AUD aHR 0.64; liraglutide aHR 0.72.

Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83; any SUD: aHR, 0.68; 95% CI, 0.54-0.85) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92; any SUD: aHR, 0.78; 95% CI, 0.64-0.97)
Read passages in the original paper

Key findings

Semaglutide and liraglutide showed the largest AUD/SUD hospitalization risk reductions; any AUD medication only aHR ~0.98; somatic hospitalizations also lower; suicide attempts not clearly changed.

Methodology

Built drug-use periods from registers and ran within-individual Cox models comparing GLP-1 agonist use vs nonuse and AUD medications vs nonuse.

Limitations

Randomized efficacy in AUD without diabetes/obesity indication, or that all GLP-1 agonists are equal.

Related papers in this topic

Same topic cluster — not a recommendation engine.